IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

(2020) Sue Han et al.   BRITISH JOURNAL OF CANCER

Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas

(2020) Enrico Franceschi et al.   EUROPEAN JOURNAL OF CANCER

A basic review on systemic treatment options in WHO grade II-III gliomas

(2020) Maximilian J. Mair et al.   CANCER TREATMENT REVIEWS

Characteristics of IDH-mutant gliomas with non-canonical IDH mutation

(2020) L. Poetsch et al.   JOURNAL OF NEURO-ONCOLOGY

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

(2020) Michael Weller et al.   Nature Reviews Clinical Oncology

Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency

(2017) Diego Avellaneda Matteo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria

(2017) Michela Visani et al.   JOURNAL OF NEURO-ONCOLOGY

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis

(2017) Maarten M J Wijnenga et al.   NEURO-ONCOLOGY

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel

(2016) Angela Zacher et al.   BRAIN PATHOLOGY

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas

(2016) Hao-Yuan Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients

(2016) Ni Chen et al.   PATHOLOGY

Oligodendroglioma: pathology, molecular mechanisms and markers

(2015) Pieter Wesseling et al.   ACTA NEUROPATHOLOGICA

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

(2015) Michael Weller et al.   ACTA NEUROPATHOLOGICA

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma

(2014) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

Next Generation Sequencing Improves the Accuracy of KRAS Mutation Analysis in Endoscopic Ultrasound Fine Needle Aspiration Pancreatic Lesions

(2014) Dario de Biase et al.   PLoS One

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma

(2014) Stefan Pusch et al.   Acta Neuropathologica Communications

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)

(2013) Dario de Biase et al.   PLoS One

A Sensitive and Specific Diagnostic Panel to Distinguish Diffuse Astrocytoma From Astrocytosis: Chromosome 7 Gain With Mutant Isocitrate Dehydrogenase 1 and p53

(2011) Sandra Camelo-Piragua et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

(2010) Philippe Metellus et al.   ACTA NEUROPATHOLOGICA

Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma

(2010) Lonneke A.M. Gravendeel et al.   HUMAN MUTATION

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA